Literature DB >> 11249727

Enhancing vaccines with immune stimulatory CpG DNA.

A M Krieg1, H L Davis.   

Abstract

Certain vertebrate immune cells have evolved receptors that detect the presence of pathogen DNA based on its content of unmethylated CpG dinucleotides in particular base contexts. This 'CpG DNA' acts as a 'danger signal', triggering protective innate and acquired immune responses. The activity of CpG DNA can be mimicked with synthetic oligodeoxynucleotides, which when added to a vaccine greatly boost the resulting immune response.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11249727

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  17 in total

1.  Aging impairs murine B cell differentiation and function in primary and secondary lymphoid tissues.

Authors:  Daniela Frasca; Bonnie B Blomberg
Journal:  Aging Dis       Date:  2011-10-28       Impact factor: 6.745

2.  Phosphorothioate-stimulated uptake of short interfering RNA by human cells.

Authors:  Marita Overhoff; Georg Sczakiel
Journal:  EMBO Rep       Date:  2005-12       Impact factor: 8.807

3.  Key differences in B cell activation patterns and immune correlates among treated HIV-infected patients versus healthy controls following influenza vaccination.

Authors:  Zhenwu Luo; Lei Ma; Lumin Zhang; Lisa Martin; Zhuang Wan; Stephanie Warth; Andrew Kilby; Yong Gao; Pallavi Bhargava; Zhen Li; Hao Wu; Eric G Meissner; Zihai Li; J Michael Kilby; Guoyang Liao; Wei Jiang
Journal:  Vaccine       Date:  2015-12-22       Impact factor: 3.641

4.  Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.

Authors:  A Campos-Neto; J R Webb; K Greeson; R N Coler; Y A W Skeiky; S G Reed
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

5.  CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.

Authors:  C L Cooper; H L Davis; M L Morris; S M Efler; M Al Adhami; A M Krieg; D W Cameron; J Heathcote
Journal:  J Clin Immunol       Date:  2004-11       Impact factor: 8.317

6.  Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.

Authors:  Pilar Nava-Parada; Guido Forni; Keith L Knutson; Larry R Pease; Esteban Celis
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

7.  Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei.

Authors:  Surasakdi Wongratanacheewin; Wannapa Kespichayawattana; Pakamas Intachote; Sathit Pichyangkul; Rasana W Sermswan; Arthur M Krieg; Stitaya Sirisinha
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

Review 8.  Antiinfective applications of toll-like receptor 9 agonists.

Authors:  Arthur M Krieg
Journal:  Proc Am Thorac Soc       Date:  2007-07

9.  A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection.

Authors:  Ali M Harandi; Kristina Eriksson; Jan Holmgren
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  DNA containing CpG motifs induces angiogenesis.

Authors:  Mei Zheng; Dennis M Klinman; Malgorzata Gierynska; Barry T Rouse
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.